What Is Nuclear Imaging?

Nuclear imaging is a branch of medical imaging in which radioactive tracers, called radiotracers, are introduced into the body and detected externally by instruments sensitive to the gamma rays or annihilation photons the tracers emit. Unlike X-ray or ultrasound imaging, which depict anatomy, nuclear imaging depicts physiological function: blood flow, metabolic activity, receptor binding, and cellular uptake. The field draws from nuclear physics, radiochemistry, detector engineering, and computational image reconstruction, and it is organizationally represented within the IEEE Nuclear and Plasma Sciences Society.

Nuclear imaging rests on the principle that a radiotracer can be designed to concentrate in specific tissues or participate in specific biochemical processes. Because the radiotracer emits radiation from inside the body, the external detector records the spatial distribution of physiological activity, providing a functional map that anatomical imaging cannot easily replicate. Quantitative accuracy and spatial resolution are constrained by detector physics, radiotracer pharmacokinetics, and the statistical nature of radioactive decay.

Gamma Camera and SPECT

The gamma camera, invented by Hal Anger in 1958, is the foundational instrument of nuclear imaging. It consists of a large sodium iodide scintillator crystal, a hexagonal collimator that selects gamma-ray directions, and an array of photomultiplier tubes that localize each scintillation event to produce a two-dimensional projection image of tracer distribution. Single-photon emission computed tomography (SPECT) extends the gamma camera to three-dimensional imaging by rotating the detector around the patient and applying filtered backprojection or iterative reconstruction algorithms to the set of acquired projections. SPECT is widely used with technetium-99m-labeled compounds for cardiac perfusion imaging, bone scanning, and sentinel lymph node detection. Clinical performance standards for SPECT systems are maintained by IEEE to ensure consistent measurement of sensitivity, resolution, and uniformity across commercial instruments.

Positron Emission Tomography

Positron emission tomography (PET) detects the two 511 keV annihilation photons produced when a positron emitted by a radiotracer annihilates with an electron in tissue. Because the two photons travel in nearly opposite directions, pairs of coincident detector events define a line of response through the body without requiring a collimator, giving PET substantially higher sensitivity than SPECT. Fluorine-18-labeled fluorodeoxyglucose (FDG) is the dominant radiotracer: it accumulates in metabolically active cells, making it the primary tool for oncologic staging, treatment response assessment, and the evaluation of dementia. Modern PET scanners use arrays of lutetium-based scintillators coupled to silicon photomultipliers, achieving spatial resolutions of 3 to 4 mm and time-of-flight capabilities that improve image signal-to-noise ratio. PET imaging performance standards define how sensitivity, scatter fraction, and count rate performance are measured and reported across scanner generations.

Energy Resolution and Radiotracer Design

Energy resolution is the ability of a detector to distinguish gamma-ray energies, expressed as the percentage width of the photopeak at half maximum relative to the peak energy. High energy resolution reduces the contribution of scattered photons to the image, improving quantitative accuracy. Sodium iodide offers roughly 10% energy resolution at 140 keV; cadmium zinc telluride (CZT) semiconductor detectors achieve 5% or better at the same energy, enabling improved isotope discrimination for multi-tracer studies. Radiotracer design is a parallel research area: chemists synthesize molecules that carry a positron-emitting or gamma-emitting isotope while retaining the biological behavior of the parent compound. Novel radiotracers for neuroimaging target amyloid plaques, tau tangles, and neuroreceptors, expanding the diagnostic scope of PET beyond oncology into neurodegenerative disease.

Applications

Nuclear imaging has applications in a wide range of medical and research fields, including:

• Oncology: tumor staging, treatment response monitoring, and radiation therapy planning using FDG-PET
• Cardiology: myocardial perfusion assessment and viability testing with SPECT and PET
• Neurology: diagnosis and staging of Alzheimer's disease, Parkinson's disease, and epilepsy
• Drug development: quantifying receptor occupancy and drug pharmacokinetics in clinical trials
• Preclinical research: small-animal PET and SPECT for evaluating novel radiotracers in disease models